Katemera Watsopano Wochiza Khansa ku China Walengezedwa

A GWIRITSANI KwaulereKutulutsidwa 8 | eTurboNews | | eTN
Avatar ya Linda Hohnholz
Written by Linda Hohnholz

Innovent Biologics, Inc. (Innovent), kampani yapamwamba kwambiri padziko lonse lapansi ya biopharmaceutical yomwe imapanga, kupanga ndi kugulitsa mankhwala apamwamba kwambiri ochizira khansa, metabolic, autoimmune ndi matenda ena akuluakulu, ndi NeoCura Bio-Medical Technology Co., Ltd. NeoCura), kampani yotsogola ya AI yothandizidwa ndi RNA precision medicine biotech yomwe idadzipereka kupanga nsanja yapamwamba kwambiri padziko lonse lapansi ya RNA, lero alengeza molumikizana kuti apanga mgwirizano kuti achite kafukufuku wazachipatala ku China pamankhwala ophatikiza a sintilimab. kuchokera ku katemera wa neoantigen wa Innovent ndi munthu payekha NEO_PLIN2101 wochokera ku NeoCura.

<

Innovent ithandizana ndi NeoCura ku China kuti awunike chitetezo, pharmacokinetics, pharmacodynamics ndi mphamvu yoyambirira ya mankhwala osakaniza pogwiritsa ntchito sintilimab kuchokera ku Innovent ndi NEO_PLIN2101 kuchokera ku NeoCura odwala khansa, kupititsa patsogolo chitukuko chachipatala cha kuphatikiza immunotherapy kwa zotupa zingapo zolimba ndikukonzekera kupereka. ntchito ya Investigational New Drug (IND) ku National Medical Products Administration (NMPA) posachedwa.

Dr. Liu Yongjun, Purezidenti wa Innovent, adati: "Ndife ochita chidwi ndi mapaipi osiyanitsa a NeoCura a R&D ndi gulu la kafukufuku wapadziko lonse lapansi, ndipo ndife okondwa kulowa mumgwirizanowu kuti tiwone kufunika kwachipatala kwa sintilimab kuphatikiza ndi katemera wa neoantigen wa zotupa zolimba. . Innovent ali ndi payipi yolimba yokhala ndi kuthekera kolimba mu immunology ndi biology ya khansa. Pakali pano, tili ndi mankhwala otsogola asanu ovomerezedwa ndi kukhazikitsidwa ku China ndipo tidzakhala ndi mankhwala opitilira 10 oti adzayambitsidwe mzaka 2-3 zikubwerazi. Pulatifomu yathu yophatikizika kwathunthu yapeza R&D yamphamvu, chitukuko chachipatala ndi luso lazamalonda ndipo ndiyabwino kwa anzathu kunyumba ndi kunja. Tikuyembekezanso kuwunikanso mipata yatsopanoyi pakukulitsa zisonyezo komanso kukulitsa mphamvu zamachiritso a sintilimab kuphatikiza ndi njira zochiritsira zatsopano. Tikuyembekezera mgwirizano waukulu komanso wozama pakati pa magulu awiriwa m'tsogolomu. “

Dr. Wang Yi, yemwe anayambitsa NeoCura, anati: “Pakadali pano, katemera wa neoantigen ndi njira yochiritsira yomwe ikukula padziko lonse lapansi. NeoCura yakhala ikuyang'ana kwambiri pa R&D ya katemera wa tumor neoantigen kuyambira pomwe idakhazikitsidwa, ndikuyembekeza kuthana ndi zovuta za immunotherapy yomwe ilipo pochiza zotupa zolimba pogwiritsa ntchito matekinoloje atsopano. Mgwirizano ndi Innovent udzachita nawo gawo limodzi la katemera wa umunthu wa neoantigen ndi mankhwala osokoneza bongo a monoclonal antibody ndikuwunikira pamodzi zotsatira zachipatala za mankhwala osakaniza pochiza zotupa zolimba, zomwe zikuyembekezeka kupititsa patsogolo kuyankha kwa khansa ya immunotherapy ndikubweretsa mwayi watsopano. kwa mankhwala ophatikiza khansa. "

ZOMWE MUNGACHITE PA NKHANIYI:

  • Innovent ithandizana ndi NeoCura ku China kuti awunike chitetezo, pharmacokinetics, pharmacodynamics ndi mphamvu yoyambirira ya mankhwala osakaniza pogwiritsa ntchito sintilimab kuchokera ku Innovent ndi NEO_PLIN2101 kuchokera ku NeoCura odwala khansa, kupititsa patsogolo chitukuko chachipatala cha kuphatikiza immunotherapy kwa zotupa zingapo zolimba ndikukonzekera kupereka. ntchito ya Investigational New Drug (IND) ku National Medical Products Administration (NMPA) posachedwa.
  • The collaboration with Innovent will play a synergistic role of personalized neoantigen vaccines and monoclonal antibody drugs and jointly explore the clinical effect of the combination therapy in the treatment of solid tumors, which is expected to improve the objective response rate of cancer immunotherapy and bring new opportunities for cancer combination regimens.
  • NeoCura has been focusing on the R&D of tumor neoantigen vaccines since its establishment, hoping to overcome the challenges of existing immunotherapy in the treatment of solid tumors through the application of new technologies.

Ponena za wolemba

Avatar ya Linda Hohnholz

Linda Hohnholz

Mkonzi wamkulu kwa eTurboNews zochokera ku eTN HQ.

Amamvera
Dziwani za
mlendo
0 Comments
Zolowetsa Pamakina
Onani ndemanga zonse
0
Mukufuna malingaliro anu, chonde yankhani.x
Gawani ku...